Processa Pharmaceuticals, Inc.
PCSA
$0.26
-$0.01-2.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.83M | 1.50M | 1.26M | 1.02M | 1.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.49M | 3.95M | 2.85M | 2.73M | 3.42M |
| Operating Income | -3.49M | -3.95M | -2.85M | -2.73M | -3.42M |
| Income Before Tax | -3.44M | -3.93M | -2.83M | -2.73M | -3.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.44M | -3.93M | -2.83M | -2.73M | -3.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.44M | -3.93M | -2.83M | -2.73M | -3.38M |
| EBIT | -3.49M | -3.95M | -2.85M | -2.73M | -3.42M |
| EBITDA | -3.49M | -3.95M | -2.85M | -2.73M | -3.42M |
| EPS Basic | -0.07 | -0.25 | -0.30 | -0.78 | -1.03 |
| Normalized Basic EPS | -0.05 | -0.16 | -0.19 | -0.49 | -0.65 |
| EPS Diluted | -0.07 | -0.25 | -0.30 | -0.78 | -1.03 |
| Normalized Diluted EPS | -0.05 | -0.16 | -0.19 | -0.49 | -0.65 |
| Average Basic Shares Outstanding | 47.53M | 15.57M | 9.53M | 3.51M | 3.28M |
| Average Diluted Shares Outstanding | 47.53M | 15.57M | 9.53M | 3.51M | 3.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |